The drug is a phosphodiesterase-4 (PDE4) inhibitor targeting an anti-inflammatory mechanism already exploited by treatments for asthma, COPD and psoriasis. These include Celgene’s Otezla ...

PALI-2108 is a phosphodiesterase-4 (PDE4) inhibitor that ... Bio begins dosing subjects in last cohort of ulcerative colitis ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

fuelled by head-to-head studies showing it was more effective at treating moderate-to-severe psoriasis than Amgen's drug, which acts as a PDE4 inhibitor. Results from the POETYK PSO-1 and POETYK ...

Roflumilast 0.3%. Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of phosphodiesterase 4 (PDE4). Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic-3 ...

However, none of the PDE4 inhibitors tested so far has reached the market, mainly owing to tolerability issues such as emesis. A study in Nature Biotechnology that sheds light on the structural ...

Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food ...

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug ... inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 ...